18F-DCFPyL PET/CT in metastatic renal cell carcinoma

Geoffrey M Currie, Marko Trifunovic, Jui Liu, Sang Kim, Howard Gurney

Research output: Contribution to journalArticlepeer-review


Targeted molecular imaging with PET uses chemical ligands that are peptides specifically targeting a receptor of interest. Prostate-specific membrane antigen (PSMA) is substantially upregulated in prostate cancer but is also expressed in the neovascular tissue of several malignancies, including renal cell carcinoma (RCC). Radiolabeled peptide targets for PSMA may be helpful in detecting metastatic RCC lesions. We present a case of incidental detection of RCC metastatic disease with PSMA-targeted PET, and we explore potential use for deliberate evaluation of RCC with PSMA-targeted tracers.
Original languageEnglish
Pages (from-to)282-285
Number of pages4
JournalJournal of Nuclear Medicine Technology
Issue number3
Early online date08 Nov 2021
Publication statusPublished - 01 Sept 2022


Dive into the research topics of '18F-DCFPyL PET/CT in metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this